Contribution: Industrial Research Assistance Program – Contributions to Firms
Vastcon Inc.
$45,555.00
Predictive Diagnostic for Cancer
FY 2018-19 · 2018-05-01
Summary
Estrogen Receptor (ER) Positive breast cancer is the most common type and can be effectively treated with endocrine therapy. However, the major challenge is the endocrine therapy resistance and breast cancer recurrence in 50% of the patients. VastCo is developing a novel predictive test that could be combined with the receptor status test for the prediction of treatment response to endocrine therapy. This test would help Clinical Oncologists to design treatment regimen for better clinical outcome.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Winnipeg|Winnipeg, Manitoba, Canada
Recipient Type
For-profit organization
Business Number
810234633
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2018-05-01 | 2018-19 | $50,000.00 |
| 2 | 2018-05-01 | 2018-19 | $45,555.00 |
As published
Additional Information
This agreement has been amended 2 time(s). The end date of this agreements has been modified by 16 days. The total amended value is -4,445 dollars.
Additional Information (French)
Cet accord a été modifié 2 fois La date de fin du présent accord a été changé de 16 jours. La valeur totale des modifications est de - 4 445 dollars.
Agreement End Date
2019-03-31
Agreement Number
906588
Agreement Start Date
2018-05-01
Agreement Title
Predictive Diagnostic for Cancer
Agreement Title (French)
Diagnostic prédictif pour le cancer
Agreement Type
Contribution
Agreement Value
$45,555.00
Amendment Date
2019-03-13
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Estrogen Receptor (ER) Positive breast cancer is the most common type and can be effectively treated with endocrine therapy. However, the major challenge is the endocrine therapy resistance and breast cancer recurrence in 50% of the patients. VastCo is developing a novel predictive test that could be combined with the receptor status test for the prediction of treatment response to endocrine therapy. This test would help Clinical Oncologists to design treatment regimen for better clinical outcome.
Description (French)
Le cancer du sein positif de récepteur d'œstrogène est le type le plus courant et peut être traité efficacement par une thérapie endocrinienne. Cependant, le défi majeur est la résistance à la thérapie endocrinienne et la réapparition du cancer du sein chez 50% des patientes. VastCo est en train de développer un nouveau test prédictif, qui pourrait être combiné avec le test de l'état des récepteurs pour la prédiction de la réponse du traitement à la thérapie endocrinienne. Ce test aiderait les oncologues cliniciens à concevoir un régime de traitement pour de meilleurs résultats cliniques.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Winnipeg South
Federal Riding (French)
Winnipeg-Sud
Federal Riding Number
46013
NAICS Code
33911
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
810234633
Recipient City
Winnipeg|Winnipeg
Recipient Country
CA
Recipient Legal Name
Vastcon Inc.
Recipient Postal Code
R3Y 0A2
Recipient Province or Territory
MB
Recipient Type
F
Reference Number
172-2018-2019-Q1-906588
